Schrödinger (SDGR) Reports +17% ACV Growth Amid Hosted Licensing Shift

Key Takeaways

• Software demand is broadening. Annual Contract Value (ACV), a measure of software bookings, grew 17% year over year in Q3 2026, driven by deeper adoption across large pharmaceutical accounts, biotech, and a fast-emerging materials science customer base.
• A hosted licensing shift is resetting revenue recognition. Hosted revenue rose 49% and reached 45% of software revenue, trading near-term reported revenue for more predictable, ratable income and supporting the goal of positive adjusted EBITDA by the end of 2028.
• New AI products are key growth catalysts. Bunsen, the company's agentic AI co-scientist, is in early access with an open beta expected this year, while the predictive toxicology platform now evaluates more than 80 off-target proteins and is already contributing to ACV.
• Therapeutics milestones provide lumpy upside. Takeda's zasocitinib (a TYK2 inhibitor co-invented by Schrödinger) is under FDA priority review with approval expected in early 2027, and partner programs carry roughly $4 billion in potential future milestones and royalties.
• Analyst sentiment is constructive but mixed on valuation. Consensus remains a "Buy" with targets recently raised across several firms, though some analysts caution that expectations are already elevated after sharp outperformance.
• Key risks include milestone concentration and cash burn. Recent revenue upside leaned heavily on a single Structure Therapeutics milestone, and the company remains unprofitable on a generally accepted accounting principles (GAAP) basis despite a $373 million cash cushion.

Strategic Positioning and Competitive Outlook

Schrödinger occupies a distinctive position at the intersection of physics-based simulation and artificial intelligence for molecular discovery. Its platform generates ground-truth training data through first-principles physics, addressing the data-scarcity problem that constrains most AI-driven drug and materials design models. This dual approach differentiates it from pure machine-learning competitors and has entrenched it across top-20 pharmaceutical companies, where management still sees meaningful room to expand spending among lower-tier accounts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Structurally, the company is broadening its total addressable market beyond drug discovery into materials science, spanning chemicals, energy storage, semiconductors, and electronics. Recent research breakthroughs, including work on lithium battery electrolytes published in the journal Nature, underscore how its platform can replace experimental trial and error with rapid computational design. Meanwhile, its co-founding strategy converts software value into equity stakes, milestones, and royalties, creating a diversified monetization flywheel. The principal structural risk is the ongoing transition to hosted licensing, which temporarily depresses reported software revenue even as it improves long-term visibility.

Major Catalysts Ahead

Several discrete events could shape investor sentiment in the coming quarters. The December presentation of SGR-1505 data at the American Society of Hematology meeting will test the company's wholly owned oncology pipeline. In parallel, a potential FDA approval of Takeda's zasocitinib in early 2027 represents a meaningful validation of Schrödinger's co-invention model and a prospective royalty stream.

The open beta launch of Bunsen is a near-term software catalyst with monetization implications, given its throughput-based pricing model. Continued expansion of the predictive toxicology panel toward commercial scale could also drive incremental ACV. On the financial side, fourth-quarter ACV typically accounts for a substantial share of annual bookings, so year-end contract closes will determine whether recently raised full-year guidance of $222–232 million is met.

Analyst actions have trended optimistic. TD Cowen raised its price target to $36, KeyBanc to $32, BMO Capital to $35, and Morgan Stanley to $29 (maintaining an Equal Weight rating), while UBS lifted its target to $30. Consensus remains a "Buy" with an average target near $26, though the dispersion of targets reflects ongoing debate over valuation after the stock's recent run.

Industry and Macroeconomic Forces

Schrödinger's trajectory is closely tied to the broader AI and biopharmaceutical funding cycles. Management has indicated that biotech financing stress has largely dissipated, supporting renewed software adoption among smaller customers. Interest-rate policy matters indirectly: lower financing costs tend to ease capital availability for discovery-stage biotechs, a key demand cohort.

The secular shift toward predict-first computational discovery is a structural tailwind as biopharma and materials organizations prioritize higher-probability, faster discovery timelines. However, the company's equity stakes and milestone-heavy drug discovery revenue introduce sensitivity to merger-and-acquisition activity and partner clinical outcomes, both of which can be volatile and difficult to forecast. Currency movements and mark-to-market swings in public equity holdings also introduce below-the-line earnings noise.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, Schrödinger's medium-term narrative rests on three pillars. First, sustained software growth of roughly 10–15% annually, supported by hosted-license adoption, new product launches, and materials science expansion, underpins the path to positive adjusted EBITDA by the end of 2028. Second, drug discovery revenue, with a stated three-year view of roughly $150 million, should be augmented by milestone and royalty events, though timing remains inherently lumpy. Third, disciplined operating expense management—already evident in a 13% year-over-year decline in Q3 2026—supports margin progression.

Long-term competitive threats include large, well-funded AI-native discovery platforms and the risk that computational adoption in materials science matures more slowly than anticipated. Regulatory dynamics cut both ways: faster approvals for partnered programs enhance milestone and royalty visibility, while clinical setbacks can remove upside quickly. Consensus expectations imply continued unprofitability in the near term, so the durability of ACV growth, the pace of Bunsen monetization, and the frequency of clinical and partnership milestones will be the primary variables shaping sentiment through 2026 and into 2027.

Using Tickeron’s Trend Prediction Engine for SDGR Analysis

In my own research on names like Schrödinger, I often turn to Tickeron’s Trend Prediction Engine to get an AI-driven view of potential short-term momentum. It helps flag whether the stock may trend bullish, bearish, or sideways over the coming weeks or months based on historical patterns and current signals. This adds a useful layer when I’m weighing the timing around catalysts like the Bunsen beta or year-end ACV closes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Allana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume